NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Corp. reported Q1 2026 financial results highlighting completion of a successful FDA End-of-Phase 2 meeting aligning study parameters for RESTORE, a pivotal trial for NVG-291 in chronic tetraplegia. Site activations are underway, targeting study initiation in mid-2026. The company completed its Nasdaq uplisting, strengthened its lead…